"Carl Langren and his team brought public company expertise to Lumos Pharma, a great asset during our merger process and transition to a publicly traded company," commented Rick Hawkins, CEO, Chairman and President of Lumos Pharma. "We are grateful for his contributions to Lumos Pharma and the advancement of our company's strategy and are pleased that the structural fabric he put in place will continue as Lori Lawley assumes the role of CFO. I am also pleased to announce the addition of Eddie Varnado as VP of Finance. Our deep bench in Finance will continue to ensure that the Company can execute on its goals with financial prudence."